|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.5510 - 0.6061|
|52-week range||0.4477 - 2.9220|
|Beta (5Y monthly)||1.64|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Invitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023.
Invitae (NYSE: NVTA), a leading medical genetics company, today announced enhanced chemistry of its Invitae Personalized Cancer Monitoring™ platform that helps detect circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies. ctDNA can provide real-time insights on patient response or disease progression, support patient prognostic stratification and enable early detection of residual disease.
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.